Navigation Links
Sangamo BioSciences Announces Closing Of $74.2 Million Public Offering Of Common Stock And Exercise Of Over-Allotment Option
Date:9/23/2013

RICHMOND, Calif., Sept. 23, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the closing of its previously announced underwritten public offering of 6,100,000 shares of its common stock, as well as 915,000 additional shares of its common stock pursuant to the full exercise of the over-allotment option granted to the underwriters.

(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)

The shares were sold at the public offering price of $10.58 per share, the last closing price of the stock on the date immediately prior to pricing.  This brings the aggregate gross proceeds from the offering to approximately $74.2 million, before deducting underwriting discounts and commissions and other offering expenses.

Lazard Capital Markets LLC, JMP Securities LLC and Piper Jaffray & Co. acted as joint book-running managers and Cowen and Company, LLC acted as co-lead manager for the offering.

The shares described above were issued pursuant to a prospectus supplement and accompanying prospectus, all as filed as part of a shelf registration statement on Form S-3 previously filed with and declared effective by the Securities and Exchange Commission ("SEC"). The company filed a final prospectus supplement relating to the offering with the SEC on September 19, 2013, which is available along with the accompanying prospectus filed with the SEC in connection with the shelf registration, on the SEC's website at www.sec.gov.  Copies of the final prospectus supplement and the accompanying prospectus may be obtained by sending a request to: Lazard Capital Markets LLC, 30 Rockefeller Plaza, 60th Floor, New York, NY 10020, or via telephone at 80
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sangamo BioSciences Proposes Public Offering Of Common Stock
2. Biotech Firms Receive Orphan Drug Designations, Release Clinical Data, Achieve Goals, Enter Acquisitions & Forecast Revenues - Research Report on Aegerion, Oncolytics, Merrimack, Sangamo, and PDL
3. Sangamo BioSciences Announces Presentation At The 2013 Wedbush Life Sciences Management Access Conference
4. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
5. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
6. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
7. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
8. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
9. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
10. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
11. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... , Alemania, April 27, 2015 ... nuevo receptor utilizando tecnología de descubrimiento de biomarcador computacional  ... el tratamiento de millones de pacientes con cáncer   ... ha recibido una patente en Europa titulada "Tissue Protective ... Molecular Health de que EPHB4 es un nuevo receptor ...
(Date:4/27/2015)... 2015 Deadly viruses such as Ebola ... of the University City Science Center's Port ... , With a $4.5 million Phase 2 SBIR grant ... Phelix Therapeutics is focused on therapies for unmet ... company is developing first-in-class protease inhibitors based on a ...
(Date:4/27/2015)... , April 27, 2015   Aratana ... pet therapeutics company focused on the licensing, development ... animals, today provided commentary on clinical study data ... a poster session at the American Association for ... ADXS31-164 is a novel Lm -LLO immunotherapy ...
(Date:4/27/2015)... HEIDELBERG , Germany , April ... need in treatment of millions of cancer patients   ... a patent in Europe entitled ... Health,s discovery that EPHB4 is a novel receptor for Erythropoietin ... stimulates the production of red blood cells and is ...
Breaking Biology Technology:Molecular Health obtiene la patente para un nuevo receptor 2Molecular Health obtiene la patente para un nuevo receptor 3New Resident of Science Center’s Port Business Incubator Targets SARS and Ebola 2Aratana Therapeutics Comments on ADXS31-164 (AT-014) Study Data Presented During Poster Session at the American Association for Cancer Research (AACR) Annual Meeting 2015 2Molecular Health Gains Patent for Novel Receptor Utilizing Computational Biomarker Discovery Technology 2
... Symbol: MSEDMONTON, April 14 /PRNewswire-FirstCall/ - BioMS Medical Corp. ... multiple sclerosis (MS), today announced that the independent Data ... phase III MAESTRO-03 trial of dirucotide in patients with ... recommended that the trial continue as per the protocol. ...
... Therapeutics, Inc., the leader in fragment-based lead discovery ... successful completion of the first phase of its ... of Biogen Idec (Nasdaq: BIIB ). ... to Zenobia,s technology and expertise in structural biology, ...
... Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) ... fiscal 2009 third quarter and nine-month period ended February ... its fiscal year 2009 now ending on February, 28. ... ended February 28, 2009 in the range of $3,400,000 ...
Cached Biology Technology:BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals 2Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 2Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 3Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 4Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 5
(Date:4/2/2015)... , April 2, 2015 ... DERMALOG by far outperforms the strongest competitors, showing ... high accuracy, the system is capable of a ... speed proves up to be ten times faster ... its runner-up performance.      (Photo: ...
(Date:4/1/2015)... Medisafe ™, the leading global medication management platform with ... Android smartphones and tablets, announces today that ... allow patients to track and correlate their adherence directly ... be able to visualize in real-time how taking medication ... glucose levels and blood pressure. "Patients need ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... from layers 3.46 billion years old suggests that not only ... atmosphere was as oxygen rich as it is today, according ... ways similar to the way this rock forms around hydrothermal ... have assumed that the hematite in ancient rocks formed by ...
... scientists from the National Institute of Oceanography and the ... research vessel Polarstern. The cooperative project Lohafex has yielded ... has dampened hopes on the potential of the Southern ... 2 ) and thus mitigate global warming. On 17 ...
... a common ingredient in over-the-counter skin creams. Recent results ... it is associated with major environmental risks. , "The ... in the ocean that has a direct impact on ... Porsbring. When Euorpean authorities assess environmental risks, they ...
Cached Biology News:Deep-sea rocks point to early oxygen on Earth 2Lohafex provides new insights on plankton ecology 2Lohafex provides new insights on plankton ecology 3Lohafex provides new insights on plankton ecology 4Drug used to treat skin conditions is a marine pollutant 2
... ApopTag Fluorescein Direct In Situ ... cells in situ by the ... fragments are tagged with a ... kit provides fluorescence staining for ...
... The CHEMICON APO-BRDU Kit is ... DNA breaks and total cellular DNA to ... The kit contains the instructions and reagents ... positive and negative control cells for assessing ...
The stirbar is used in the buffer tank of the Trans-Blot Plus cell to maintain uniform conductivity and temperature during electrophoretic transfer. Dimensions are 3.5 x 0.5 in....
... FXP is the latest entry in the Biomek ... accuracy and increased robustness, it can meet the ... be configured with either one or two pipetting ... FXP sets the standard for flexible laboratory solutions ...
Biology Products: